In this study, our aim is to investigate whether AS-IV can improve HFD-induced hepatic steatosis by inhibiting the expression of TLR4, MyD88, and NF-κB in the liver tissue of NAFLD rats. This evidence concerns the gene MYD88 and metabolic dysfunction-associated steatotic liver disease.